143 related articles for article (PubMed ID: 16601901)
1. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I.
Anbu AT; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Feb; 29(1):230-1. PubMed ID: 16601901
[TBL] [Abstract][Full Text] [Related]
2. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.
Lin HY; Lin SP; Chuang CK; Chen MR; Chen BF; Wraith JE
J Inherit Metab Dis; 2005; 28(6):1146-8. PubMed ID: 16435211
[TBL] [Abstract][Full Text] [Related]
3. Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I (Hurler-Scheie) treated with enzyme replacement therapy (laronidase, Aldurazyme).
Cáceres-Marzal C; García-Reymundo M; Solana J; de Arévalo B; Vaquerizo J; Galán E
Am J Med Genet A; 2008 Jul; 146A(13):1768-70. PubMed ID: 18546328
[No Abstract] [Full Text] [Related]
4. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient.
Soutar RL; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Aug; 29(4):590. PubMed ID: 16830264
[TBL] [Abstract][Full Text] [Related]
5. Alpha-L-iduronidase (laronidase; aldurazyme).
Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
[No Abstract] [Full Text] [Related]
6. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
7. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
Thomas JA; Jacobs S; Kierstein J; Van Hove J
J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
[TBL] [Abstract][Full Text] [Related]
8. [Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis].
Vélez-Díaz-Pallarés M; Sánchez Cuervo M; Martínez-Pardo Casanova M; Bermejo Vicedo T
Farm Hosp; 2012; 36(1):55-6. PubMed ID: 21641259
[No Abstract] [Full Text] [Related]
9. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
10. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
11. Laronidase opens door to treat other rare disorders.
Morrow T
Manag Care; 2004 Jun; 13(6):52-3. PubMed ID: 15259445
[No Abstract] [Full Text] [Related]
12. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
[TBL] [Abstract][Full Text] [Related]
13. Laronidase.
BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
[TBL] [Abstract][Full Text] [Related]
14. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
[TBL] [Abstract][Full Text] [Related]
16. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
[TBL] [Abstract][Full Text] [Related]
17. Laronidase hypersensitivity and desensitization in type I mucopolysaccharidosis: a case report.
Ensina LF; Aranda CS; de Lacerda AE; Camelo-Nunes I; Sole D; Martins AM; Castells M
Pediatr Allergy Immunol; 2014 Aug; 25(5):498-9. PubMed ID: 25313426
[No Abstract] [Full Text] [Related]
18. 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I.
Pjetraj D; Santoro L; Sgattoni C; Padella L; Zampini L; Monachesi C; Gabrielli O; Catassi C
Am J Med Genet A; 2023 Feb; 191(2):564-569. PubMed ID: 36333985
[TBL] [Abstract][Full Text] [Related]
19. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
Wraith JE
Expert Opin Pharmacother; 2005 Mar; 6(3):489-506. PubMed ID: 15794739
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
